Luye Pharma Group’s partner PharmaMar announced that its innovative anticancer drug, Lurbinectedin, has been added to the National Comprehensive Cancer Network’s (NCCN®) Clinical Practice ...
Luye Pharma Group today announced that it has entered into an exclusive promotion agreement with Moksha8 Brasil Distribuidora e Representação de Medicamentos Ltda. and Moksha8 Farmac&eac...
Luye Pharma Group is accelerating its biopharmaceutical pipeline globally. Shandong Boan Biological Technology Co. Ltd, the holding subsidiary of Luye Pharma Group, has recently submitted the investig...
Luye Pharma Group announced that the marketing authorization application for the company's oncology product, LY01008 (Bevacizumab injection), has been accepted by the China Center for Drug Evaluat...
Expert Committee on Breast Cancer of the Chinese Society of Clinical Oncology (CSCO BC), an authoritative Chinese oncology institution, recently published the 2020 CSCO Guidelines on Diagnosis and Tre...
Singapore, April 6, 2020: Luye Medical Group today donated surgical face masks to the Singapore Cancer Society to help cancer patients combat the COVID-19 outbreak. Kenneth Foo, Deputy Director of Sin...
Luye Pharma Group (02186.HK) reported its financial results for 2019 on March 27, 2020. According to the results, the company has achieved a total revenue of RMB 6.358 billion, up 22.9% year-on-year. ...
Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment...
Luye Pharma Group has announced that it has entered into an exclusive distribution and marketing service agreement with Cipla Medpro South Africa (Pty) Limited (Cipla Medpro), for Seroquel® and Seroqu...
PharmaMar, one of Luye Pharma’s collaborative partners, has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review the New Drug Application (NDA)...
TOP